Main > > >GEJ CANCER. *

---

Treat.: PembrolizuMAb. (METASTATIC or RECURRENT PD-L1+).
GEJ: Gastro Esophageal Junction.
>& If .. HER2/neu-Targeted Therapy
>2 Prior Fluoropyrimidine- & Pt-CT
Companion Diagnostics>
>Company : Agilent Technologies
>Name : Dako PD-L1 IHC 22C3 pharmDx
>USA Approval Date: 2017. 09.22.
USA Approval Date : 2017. 09.22.
(*) Company : Merck & Co. Inc.
TradeMark: Keytruda.
Web-Site : www.keytruda.com
UpDate: 2018. 10.02.




Treat.: TrastuzuMAb. BioSimilar.
(METASTATIC)
GEJ: Gastro ESophageal Junction.
USA Launch Date: 2019. 07.18.
(*) Company : Amgen.
TradeMark: KANJINTI
UpDate: 2019. 11.12.




Treat.: TrastuzuMAb. BioSimilar.
(METASTATIC)
GEJ: Gastro Esophageal Junction.
USA Approval Date: 2019. 03.11.
(*) Company : Pfizer.
TradeMark: TRAZIMERA
UpDate: 2019. 03.13.




Treat.: TrastuzuMAb Deruxtecan
(locally advanced or metastatic HER2-+)
USA Approval Date: 2021. 01.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.10.




Treat.: Trifluridine+ Tipiracil Tablets.
(METASTATIC)
>Previously Treat.>2 CT>Fluoropyrimi-dine, a Platinum, either a Taxane or Irinotecan, ..
USA Approval Date: 2019. 02.25.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.26.




>GEJ CANCER. *'s products
This section has no products